Gland Pharma
Ticker > Company >

Gland Pharma share price

Gland Pharma Ltd.

NSE: GLAND BSE: 543245 SECTOR: Pharmaceuticals & Drugs  2.22 L   748   133

1986.95
-34.35 (-1.70%)
BSE: 17 Sep 04:01 PM

Price Summary

Today's High

₹ 2041.95

Today's Low

₹ 1973

52 Week High

₹ 2130

52 Week Low

₹ 1200

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 32736.28 Cr.

Enterprise Value

₹ 30306.21 Cr.

No. of Shares

16.48 Cr.

P/E

28.81

P/B

3.27

Face Value

₹ 1

Div. Yield

0.91 %

Book Value (TTM)

₹  608.43

CASH

₹ 2432.62 Cr.

DEBT

₹ 2.55 Cr.

Promoter Holding

51.83 %

EPS (TTM)

₹  68.96

Sales Growth

-1.23%

ROE

11.62 %

ROCE

15.87%

Profit Growth

4.45 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Gland Pharma Ltd.

Acris Chlostin Cutenox Cutinorm Glanpan Heplock Hep 5 Larinox Tezcort Glanikinase

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-1.23%
3 Year-2.2%
5 Year9.35%

Profit Growth

1 Year4.45%
3 Year-3.49%
5 Year7.11%

ROE%

1 Year11.62%
3 Year11.41%
5 Year14.76%

ROCE %

1 Year15.87%
3 Year15.5%
5 Year19.87%

Debt/Equity

0.0003

Price to Cash Flow

30.49

Interest Cover Ratio

65.1759

CFO/PAT (5 Yr. Avg.)

0.776417020185758

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 51.83 0.00
Mar 2025 51.83 0.00
Dec 2024 51.83 0.00
Sep 2024 51.83 0.00
Jun 2024 51.83 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 65.1759.
  • The Company has been maintaining an effective average operating margins of 33.7899592998084% in the last 5 years.
  • Company has a healthy liquidity position with current ratio of 11.0106.
  • The company has a high promoter holding of 51.83%.

 Limitations

  • The company has shown a poor profit growth of -3.48607627383558% for the Past 3 years.
  • The company has shown a poor revenue growth of -2.20358346468723% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 1012.02 1062.99 1010.78 1030.35 1038.84
Total Expenditure 718.47 699.19 619.64 636.23 679.99
Operating Profit 293.55 363.8 391.14 394.12 358.85
Other Income 48.49 57.8 65.06 43.72 54.74
Interest 0.91 0.17 18.31 3.45 7.44
Depreciation 40.82 41.62 43.77 43.07 43.77
Exceptional Items 0 0 0 0 0
Profit Before Tax 300.32 379.82 394.13 391.32 362.38
Tax 77.39 98.11 99.01 101.32 93.13
Profit After Tax 222.92 281.71 295.12 290 269.26
Adjusted EPS (Rs) 13.53 17.1 17.91 17.6 16.34

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 3462.88 4400.71 3616.53 4167.43 4116.15
Total Expenditure 2160.61 2890.07 2597.98 2758.65 2673.53
Operating Profit 1302.27 1510.64 1018.55 1408.78 1442.62
Other Income 134.78 223.94 240.46 166.67 215.08
Interest 3.41 5.24 7.41 7.84 22.84
Depreciation 98.78 110.3 146.74 162.11 169.27
Exceptional Items 0 0 -56.46 0 0
Profit Before Tax 1334.85 1619.04 1048.4 1405.5 1465.59
Tax 337.85 406.89 272.58 362.17 375.83
Net Profit 997.01 1212.16 775.83 1043.33 1089.75
Adjusted EPS (Rs.) 60.95 73.78 47.11 63.34 66.14

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 16.36 16.43 16.47 16.47 16.48
Total Reserves 5886.93 7141.8 7936.83 8978.82 9738.63
Borrowings 3.93 3.82 3.26 2.55 1.11
Other N/C liabilities 76.38 90.15 86.42 129.05 141.64
Current liabilities 512.46 581.94 730.2 414.2 523.77
Total Liabilities 6496.06 7834.14 8773.18 9541.09 10421.62
Assets
Net Block 954.23 1502.19 1570.55 1693.73 1744.99
Capital WIP 337.81 180.75 177.22 120.01 42.21
Intangible WIP 0 10 0 0 0
Investments 0.55 8.16 8.16 2385.74 2789.57
Loans & Advances 77.97 286.4 128.92 114.38 77.89
Other N/C Assets 2.43 2.21 0 655.91 0
Current Assets 5123.07 5844.44 6888.34 4571.33 5766.96
Total Assets 6496.06 7834.14 8773.18 9541.09 10421.62
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 1334.85 1619.04 1048.4 1405.5 1465.59
Adjustment 17.3 -28.19 37.38 23.15 -5.15
Changes in Assets & Liabilities -435.8 -393.05 -407 23.38 -34.59
Tax Paid -311.43 -406.51 -310.89 -316.05 -352.17
Operating Cash Flow 604.93 791.29 367.89 1135.97 1073.67
Investing Cash Flow -1520.97 -1006.92 1211.22 -2917.58 1582.29
Financing Cash Flow 1238.46 34.9 14.92 -7.4 -339.54
Net Cash Flow 322.42 -180.73 1594.04 -1789.01 2316.42

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 51.83 51.83 51.83 51.83 51.83
fosun pharma industrial p... 51.83 51.83 51.83 51.83 51.83
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 48.17 48.17 48.17 48.17 48.17
government pension fund g... - - - 1.42 1.49
hdfc mutual fund - hdfc m... - - - - 6.57
icici prudential india op... 3.18 4.76 4.68 4.74 5.08
llp 0.04 0.04 0.03 - 0.03
mirae asset large & midca... 6.85 7.61 7.52 6.78 6.24
nippon life india trustee... 6.33 6.32 6.21 6.07 6.11
sbi large & midcap fund 3.30 3.18 3.18 3.19 2.91
uti-flexi cap fund - - - 1.16 1.16
hdfc mutual fund - hdfc m... 6.17 6.40 6.63 6.56 -
aditya birla sun life tru... 1.70 1.37 1.12 - -
uti flexi cap fund 1.48 1.28 1.22 - -

Annual Reports

Title Link
Title Link
Annual Report 2025
Annual Report 2024
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY25
Concall Q4FY23
Concall Q4FY22
Concall Q4FY21
Concall Q3FY24
Concall Q3FY22
Concall Q3FY22
Concall Q3FY21
Concall Q1FY22
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY24
Presentation Q4FY21
Presentation Q3FY25
Presentation Q3FY24
Presentation Q3FY21
Presentation Q2FY24
Presentation Q2FY23
Presentation Q2FY23
Presentation Q2FY22
Presentation Q1FY23
Presentation Q1FY22

Company News

Gland Pharma Stock Price Analysis and Quick Research Report. Is Gland Pharma an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Gland Pharma. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Gland Pharma has a PE ratio of 28.8141516944937 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Gland Pharma has ROA of 10.9179% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Gland Pharma has a Current ratio of 11.0106.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Gland Pharma has a ROE of 11.6247%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Gland Pharma has a Debt to Equity ratio of 0.0003 which means that the company has low proportion of debt in its capital.

  • Sales growth: Gland Pharma has reported revenue growth of -1.2305% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Gland Pharma for the current financial year is 35.0477594469977%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Gland Pharma is Rs 18 and the yield is 0.9045%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Gland Pharma is Rs 68.9557. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Gland Pharma in Ticker for free. Also, one can get the intrinsic value of Gland Pharma by using Valuation Calculators, which are available with a Finology ONE subscription. 

Gland Pharma FAQs

Q1. What is Gland Pharma share price today?
Ans: The current share price of Gland Pharma is Rs 1986.9.

Q2. What is the market capitalisation of Gland Pharma?
Ans: Gland Pharma has a market capitalisation of Rs 32735.45368587 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Gland Pharma?
Ans: The PE ratio of Gland Pharma is 28.8141516944937 and the P/B ratio of Gland Pharma is 3.26560733163279, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Gland Pharma share?
Ans: The 52-week high share price of Gland Pharma is Rs 2131, and the 52-week low share price of Gland Pharma is Rs 1277.8.

Q5. Does Gland Pharma pay dividends?
Ans: Currently, Gland Pharma pays dividends. Dividend yield of Gland Pharma is around 0.9045%.

Q6. What are the face value and book value of Gland Pharma shares?
Ans: The face value of Gland Pharma shares is Rs 1, while the book value per share of Gland Pharma is around Rs 608.432. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Gland Pharma?
Ans: Gland Pharma has a total debt of Rs 2.551 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Gland Pharma?
Ans: The ROE of Gland Pharma is 11.6247% and ROCE of Gland Pharma is 15.8713%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Gland Pharma a good buy for the long term?
Ans: The Gland Pharma long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Gland Pharma undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Gland Pharma appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Gland Pharma’s financials?
Ans: You can review Gland Pharma’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Gland Pharma

Gland Pharma Ltd. Financials: Check Share Price, Balance Sheet, Annual Report and Quarterly Results for Company Analysis

 

Gland Pharma Ltd. is a leading pharmaceutical company in India that specializes in the production of injectables. As a long-term stock investor, it is important to analyze the company's financials and performance to make informed investment decisions.  We will discuss various aspects of Gland Pharma Ltd.'s stock analysis page, including its share price, balance sheet, annual report, dividend, quarterly result, stock price, price chart, news, concall, transcripts, investor presentations, promoters, and shareholders.

Gland Pharma Ltd. Share Price

The share price of Gland Pharma Ltd. is an important factor to consider when analyzing the company's stock. It reflects the market's perception of the company's financial performance and growth prospects. Our pre-built screening tools enable investors to track the company's share price and monitor any fluctuations in real-time.

Gland Pharma Ltd. Balance Sheet

The balance sheet of Gland Pharma Ltd. provides a snapshot of the company's financial position at a specific point in time. It includes assets, liabilities, and equity. Ticker premium features allow for fair value calculation using tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis. These tools enable investors to analyze the company's financial performance and make informed investment decisions.

Gland Pharma Ltd. Annual Report

The annual report of Gland Pharma Ltd. provides a comprehensive overview of the company's financial performance and operations over the past year. It includes information on the company's revenue, expenses, profits, and losses. Ticker provides downloadable annual reports that investors can use to analyze the company's performance and make informed investment decisions.

Gland Pharma Ltd. Dividend

Gland Pharma Ltd. has a history of paying dividends to its shareholders. The company's dividend policy reflects its financial performance and growth prospects. Investors can use our pre-built screening tools to track the company's dividend payments and monitor any changes in the dividend policy.

Gland Pharma Ltd. Quarterly Result

The quarterly result of Gland Pharma Ltd. provides information on the company's financial performance and operations over the past quarter. It includes information on the company's revenue, expenses, profits, and losses. Ticker provides downloadable quarterly results that investors can use to analyze the company's performance and make informed investment decisions.

Gland Pharma Ltd. Stock Price

The stock price of Gland Pharma Ltd. reflects the market's perception of the company's financial performance and growth prospects. Ticker pre-built screening tools enable investors to track the company's stock price and monitor any fluctuations in real-time.

Gland Pharma Ltd. Price Chart

The price chart of Gland Pharma Ltd. provides a visual representation of the company's stock price over a specific period. It enables investors to track the company's stock price trends and make informed investment decisions.

Gland Pharma Ltd. News

Ticker provides the latest news and updates on Gland Pharma Ltd. Investors can use this information to stay up-to-date on the company's performance and make informed investment decisions.

Gland Pharma Ltd. Concall

The concall of Gland Pharma Ltd. provides a platform for the company's management to discuss its financial performance and operations with investors. Ticker provides transcripts of the company's concalls that investors can use to analyze the company's performance and make informed investment decisions.

Gland Pharma Ltd. Transcripts

Ticker provides transcripts of Gland Pharma Ltd. 's concalls and investor presentations. Investors can use this information to analyze the company's performance and make informed investment decisions.

Gland Pharma Ltd. Investor Presentations

The investor presentations of Gland Pharma Ltd. provide a comprehensive overview of the company's financial performance and operations. Ticker provides downloadable investor presentations that investors can use to analyze the company's performance and make informed investment decisions.

Gland Pharma Ltd. Promoters

The promoters of Gland Pharma Ltd. are a group of individuals who have a significant stake in the company. They play an important role in the company's management and decision-making processes. Investors can use Ticker pre-built screening tools to track the company's promoters and monitor any changes in their stake.

Gland Pharma Ltd. Shareholders

The shareholders of Gland Pharma Ltd. are individuals or institutions who own a stake in the company. They play an important role in the company's decision-making processes. Investors can use our pre-built screening tools to track the company's shareholders and monitor any changes in their stake.

Gland Pharma Ltd. ROCE

Return on Capital Employed (ROCE) is a crucial financial metric that assesses a company's efficiency in generating profits from its capital investments. Access the ROCE data for Gland Pharma Ltd. on our stock analysis page in the financials table or ratio section. This metric provides insights into the company's capital utilization efficiency and allows for performance comparisons within the industry. Obtain the ROCE data for Gland Pharma Ltd. here.

Gland Pharma Ltd. EBITDA

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is a significant metric that illustrates a company's operational profitability. Find the EBITDA data for Gland Pharma Ltd. on our stock analysis page in the financials table or ratio section. Analyzing EBITDA provides insights into the company's core business profitability and its ability to generate cash flow from operations. Access the EBITDA data for Gland Pharma Ltd. here.

Gland Pharma Ltd. DPS

Dividends Per Share (DPS) represents the amount of dividends distributed to each outstanding share. Discover the DPS data for Gland Pharma Ltd. on our stock analysis page in the financials table or ratio section. The DPS data helps investors evaluate the company's dividend distribution policy and its potential as an income-generating investment. Access the DPS data for Gland Pharma Ltd. here.

Gland Pharma Ltd. EPS

Earnings Per Share (EPS) measures a company's profitability on a per-share basis, providing insights into its earnings performance and growth potential. On our stock analysis page, you can find the EPS data for Gland Pharma Ltd. in the financials table or ratio section. Analyzing the EPS enables investors to assess the company's profitability trends and make informed investment decisions. Access the EPS data for Gland Pharma Ltd. here. 

Gland Pharma's Equity and Liabilities Growth

Gland Pharma's financial stability reflects in a consistent increase in total reserves from Rs. 3,630.74 Cr. in March 2020 to a robust Rs. 8,978.82 Cr. by March 2024. The share capital has remained stable at Rs. 16.47 Cr. from March 2023 to March 2024, ensuring shareholder's equity is steady. Interestingly, the borrowings have shown an impressive decrease, indicating a stronger financial position with less reliance on debt, down from Rs. 4.07 Cr. in March 2020 to just Rs. 2.55 Cr. in March 2024.

Gland Pharma's Asset Expansion

On the assets front, Gland Pharma showcases growth in its net block, rising from Rs. 968.10 Cr. in March 2020 to Rs. 1,693.73 Cr. by March 2024. This emphasizes the company's investment in tangible assets for future productivity. Moreover, there's a significant leap in investments from a mere Rs. 0.55 Cr. in March 2021 to a substantial Rs. 2,385.74 Cr. in March 2024, potentially indicating strategic diversification or expansion.

Gland Pharma's Comprehensive Balance Sheet Analysis

Gland Pharma's overall balance sheet portrays a resilient and growing financial standing. The total liabilities of the company have expanded from Rs. 4,086.04 Cr. to Rs. 9,541.09 Cr. over the span of four years, matching the total assets to maintain a balanced sheet. Current assets have seen fluctuations but stood at Rs. 4,571.33 Cr. in March 2024. The consistencies and growth patterns reflect careful financial planning and strategic asset management.

The data provided is an analysis for the Standalone Balance Sheet of the company.

The continuous evolution in Gland Pharma's financials could be an essential factor for investors performing stock screening and evaluating market trends in the pharmaceutical sector.

Read More
X